• Phone: +1-631-791-1145
  • Email: sales@imarcgroup.com

Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

The global oncology biosimilars market is expected to grow at a CAGR of 25% during 2019-2024. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Global Oncology Biosimilars Market Report

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

IMARC Group’s latest report provides a deep insight into the global oncology biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the oncology biosimilars market in any manner.

Report Coverage:

  • Historical, Current and Future Market Trends
     
  • Market Breakup by Drug Type:
    • Monoclonal Antibody
    • Immunomodulators
    • G-CSF
    • Hematopoietic Agents
    • Others
       
  • Market Breakup by Cancer Type:
    • Lung Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Breast Cancer
    • Kidney Cancer
    • Stomach Cancer
    • Brain Cancer
    • Others
       
  • Market Breakup by Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Others
       
  • Market Breakup by Region:
    • Europe
    • Asia Pacific
    • North America
    • Middle East and Africa
    • Latin America
       

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon, Celltrion Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Mylan, Hospira, F Hoffmann-La Roche, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Oncology Biosimilars Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Market Breakup by Drug Type
    5.4    Market Breakup by Cancer Type
    5.5    Market Breakup by Distribution Channel
    5.6    Market Breakup by Region
    5.7    Market Forecast
6    Market Breakup by Drug Type 
    6.1    Monoclonal Antibody
        6.1.1    Market Trends
        6.1.2    Market Forecast
    6.2    Immunomodulators
        6.2.1    Market Trends
        6.2.2    Market Forecast
    6.3    G-CSF 
        6.3.1    Market Trends
        6.3.2    Market Forecast
    6.4    Hematopoietic Agents 
        6.4.1    Market Trends
        6.4.2    Market Forecast
    6.5    Others  
        6.5.1    Market Trends
        6.5.2    Market Forecast
7    Market Breakup by Cancer Type
    7.1    Lung Cancer
        7.1.1    Market Trends
        7.1.2    Market Forecast
    7.2    Colorectal Cancer
        7.2.1    Market Trends
        7.2.2    Market Forecast
    7.3    Cervical Cancer
        7.3.1    Market Trends
        7.3.2    Market Forecast
    7.4    Breast Cancer
        7.4.1    Market Trends
        7.4.2    Market Forecast
    7.5    Kidney Cancer
        7.5.1    Market Trends
        7.5.2    Market Forecast
    7.6    Stomach Cancer
        7.6.1    Market Trends
        7.6.2    Market Forecast
    7.7    Brain Cancer
        7.7.1    Market Trends
        7.7.2    Market Forecast
    7.8    Others
        7.8.1    Market Trends
        7.8.2    Market Forecast
8    Market Breakup by Distribution Channel
    8.1    Hospital Pharmacies
        8.1.1    Market Trends
        8.1.2    Market Forecast
    8.2    Online Pharmacies
        8.2.1    Market Trends
        8.2.2    Market Forecast
    8.3    Retail Pharmacies
        8.3.1    Market Trends
        8.3.2    Market Forecast
    8.4    Others
        8.4.1    Market Trends
        8.4.2    Market Forecast
9    Market Breakup by Region
    9.1    Europe
        9.1.1    Market Trends
        9.1.2    Market Forecast
    9.2    Asia Pacific
        9.2.1    Market Trends
        9.2.2    Market Forecast
    9.3    North America
        9.3.1    Market Trends
        9.3.2    Market Forecast
    9.4    Middle East and Africa
        9.4.1    Market Trends
        9.4.2    Market Forecast
    9.5    Latin America
        9.5.1    Market Trends
        9.5.2    Market Forecast
10    SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis
12    Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Biocon
        14.3.2    Celltrion Inc.
        14.3.3    Dr. Reddy's Laboratories
        14.3.4    Intas Pharmaceuticals Ltd.
        14.3.5    STADA Arzneimittel AG
        14.3.6    Pfizer Inc.
        14.3.7    Apotex Inc.
        14.3.8    Teva Pharmaceutical Industries Ltd.
        14.3.9    Sandoz International GmbH
        14.3.10     BIOCAD
        14.3.11     Mylan
        14.3.12     Hospira
        14.3.13     F Hoffmann-La Roche

List of Figures

Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2013-2018
Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2018
Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2018
Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2018
Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2018
Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2019-2024
Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
Figure 10: Global: Oncology Biosimilars Industry: Porter’s Five Forces Analysis
Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2013 & 2018
Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2013 & 2018
Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2013 & 2018
Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2013 & 2018
Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2013 & 2018
Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2013 & 2018
Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2013 & 2018
Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2013 & 2018
Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2019-2024
Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2013 & 2018
Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2019-2024
Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2013 & 2018
Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2019-2024
Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2013 & 2018
Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2019-2024
Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024


List of Tables

Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2018 and 2024
Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2019-2024
Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2019-2024
Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2019-2024
Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2019-2024
Table 6: Global: Oncology Biosimilars Market Structure
Table 7: Global: Oncology Biosimilars Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Purchase Options




$ 1999

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com

Social Links